← Back to Search

Stem Cell Therapy

Exosomes + Microneedling for Male Pattern Baldness

Phase 1
Waitlist Available
Led By Eyal K Levit, M.D.
Research Sponsored by Levit Dermatology
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participant is experiencing hair loss and is diagnosed with Androgenetic Alopecia.
Be older than 18 years old
Must not have
Patients cannot have open wounds, eczema, or psoriatic plaques on the treatment area of the scalp
Patients who are undergoing or have undergone chemotherapy and or radiation therapy within the past 6 months
Timeline
Screening 3 weeks
Treatment Varies
Follow Up patients will self-report on questionnaire during monthly visits for the entire 1-year duration
Awards & highlights

Summary

"This trial aims to find out if using stem cell-derived exosomes with microneedling on the scalp can help treat pattern hair loss, also known as Androgenetic Alopecia."

Who is the study for?
This trial is for men and women with Androgenetic Alopecia, which includes male pattern baldness and alopecia areata. Participants should be looking for treatment options.
What is being tested?
The study tests the effectiveness of microneedling the scalp with two different doses of exosomes derived from Wharton's Jelly mesenchymal stem cells to treat hair loss.
What are the potential side effects?
Potential side effects may include discomfort or pain at the treatment site, redness, swelling, infection risk at needle entry points, and possible allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am losing my hair and have been diagnosed with Androgenetic Alopecia.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have open wounds or skin conditions like eczema on my scalp.
Select...
I have had chemotherapy or radiation therapy in the last 6 months.
Select...
I have a history of an autoimmune disorder affecting my skin.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~participants will self-report adverse events during monthly visits for the entire 1-year duration
This trial's timeline: 3 weeks for screening, Varies for treatment, and participants will self-report adverse events during monthly visits for the entire 1-year duration for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Hair color
Hair count
Hair thickness
Secondary study objectives
Adverse events
Self-reported hair changes

Trial Design

2Treatment groups
Experimental Treatment
Group I: 50 billion exosome groupExperimental Treatment1 Intervention
This arm receives 50 billion WJMSC-exosome treatment on one half of the aforementioned treatment area and an equivalent volume of placebo on the contralateral half of the treatment area.
Group II: 5 billion exosome groupExperimental Treatment1 Intervention
This arm receives 5 billion WJMSC-exosome treatment on one side of the aforementioned treatment area and an equivalent volume of placebo on the contralateral half of the treatment area.

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Dorisca Research Consulting, LLCUNKNOWN
ResilielleTM Age ZeroTM ExosomesUNKNOWN
Levit DermatologyLead Sponsor
~67 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top